Who are Diet+pravastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, Ezetimibe + Simvastatin, EZE/simvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diet-pravastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Diet+pravastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diet+pravastatin (Diet+pravastatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin (HMG-CoA reductase inhibitor). Area: Cardiovascular.

marketed Statin (HMG-CoA reductase inhibitor) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Diet+pravastatin (Diet+pravastatin) — Mitsukoshi Health and Welfare Foundation. A combination therapy that uses dietary intervention alongside pravastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diet+pravastatin TARGET	Diet+pravastatin	Mitsukoshi Health and Welfare Foundation	marketed	Statin (HMG-CoA reductase inhibitor)	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
Ezetimibe + Simvastatin	Ezetimibe + Simvastatin	Organon and Co	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
EZE/simvastatin	EZE/simvastatin	Azienda Ospedaliero Universitaria di Sassari	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Statin (HMG-CoA reductase inhibitor) class)

Organon and Co · 2 drugs in this class
AstraZeneca · 1 drug in this class
Mitsukoshi Health and Welfare Foundation · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Shenyang Northern Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diet+pravastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/diet-pravastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab